Despite advances in cardiac care, individuals with diabetes presenting with Acute Coronary Syndromes (ACS) remain at a higher risk for mortality and heart failure compared to those without diabetes. Paradoxically, these patients are often less likely to receive evidence-based interventions. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding the management of acute hyperglycemia, the use of invasive strategies, and essential pharmacotherapy.
Key Topics Covered:
The “Treatment Gap”: Memorizing the evidence that people with diabetes are statistically less likely to receive thrombolysis, revascularization, and cardioprotective medications despite having worse prognoses.
Glycemic Targets: Recalling the specific protocol for managing hyperglycemia (random glucose >11.0 mmol/L) during ACS, with a target range of 7.0–10.0 mmol/L.
Pharmacotherapy: Identifying the indications for Dual Antiplatelet Therapy (DAPT), ACE inhibitors, and beta-blockers in the post-MI setting.
Invasive Strategies: Understanding the clear benefits of early angiography and revascularization over medical management alone for this population.
Risk Stratification: Recognizing admission hyperglycemia as an independent predictor of short- and long-term mortality.